沙库巴曲缬沙坦治疗高血压合并慢性肾脏病的效果分析  

Effect analysis ofsacubitril/valsartan in the treatment of hypertension complicated with chronic kidney disease

作　　者：管红斌[1] 李峻[2] 何凯平[3] 吕路[1] GUAN Hong-bin;LI Jun;HE Kai-ping(Department of Nephrology,The First Affiliated Hospital of Guangdong Pharmaceutical University,Guangzhou 510080,China;不详)

机构地区：[1]广东药科大学附属第一医院肾内科,广州510080 [2]广东药科大学附属第一医院门诊部,广州510080 [3]广东药科大学附属第一医院病案统计科,广州510080

出　　处：《中国处方药》2023年第2期103-106,共4页Journal of China Prescription Drug

摘　　要：目的 观察沙库巴曲缬沙坦治疗高血压合并慢性肾脏病的疗效及安全性。方法 选取广东药科大学附属第一医院肾内科门诊于2021年1月~2022年1月就诊的66例高血压合并慢性肾脏病患者作为研究对象,应用随机数字表法分为对照组33例与观察组33例,对照组患者采用缬沙坦治疗12周,观察组患者采用沙库巴曲缬沙坦治疗12周,比较两组患者治疗前后的收缩压(SBP)、舒张压(DBP)、血尿素氮(BUN)、血肌酐(SCr)、尿微量白蛋白/尿肌酐(UACR)水平及不良反应。结果 治疗前,比较两组患者SBP、DBP、BUN、SCr及UACR的水平,差异均无统计学意义(P> 0.05);治疗后,观察组患者SBP、DBP的水平分别为(129.56±5.79)mmHg、(83.76±2.98)mmHg,明显低于对照组的(136.43±5.33)mmHg、(89.46±3.06)mmHg,差异均有统计学意义(P <0.05);治疗后,观察组患者BUN、SCr、UACR的水平分别为(9.27±2.49)mmol/L、(95.67±21.78)μmol/L、(90.93±35.39)mg/g,明显低于对照组的(11.56±3.12)mmol/L、(110.25±22.51)μmol/L、(111.82±39.56)mg/g,差异均有统计学意义(P <0.05)。结论 沙库巴曲缬沙坦可有效控制高血压合并慢性肾脏病患者的血压,改善肾功能,不良反应少。Objective To observe the efficacy and safety of sacubitril/valsartan in the treatment of hypertension complicated with chronic kidney disease(CKD). Methods A total of 66 patients with hypertension complicated with CKD admitted tothe Outpatient department of Nephrology of the First Affiliated Hospital of Guangdong Pharmaceutical University from January 2021 to January 2022 were prospectively selected as study subjects. These patients were divided into the control group(n = 33) and the observation group(n = 33) according to the random number table method. The control group was given valsartan for 12 weeks, and the observation group was was given sacubitril/valsartan for 12 weeks. The levels of systolic blood pressure(SBP), diastolic blood pressure(DBP), blood urea nitrogen(BUN), blood creatinine(SCr), urinary microalbumin/urinary creatinine(UACR) and adverse reactions were compared between the two groups before and after treatment. Results Before treatment, there was no statistically significant difference between the two groups in the levels of SBP, DBP, BUN, SCr and UACR(P > 0.05). After treatment, the levels of SBP and DBP in the observation group were(129.56±5.79) mmHg and(83.76±2.98) mmHg, which were lower than(136.43±5.33) mmHg and(89.46±3.06) mmHg in the control group,with statistically significant differences(P < 0.05). After treatment, the levels of BUN, SCr and UACR in the observation group were(9.27±2.49) mmol/L,(95.67±21.78) μmol/L and(90.93±35.39) mg/g, respectively, which were lower than(11.56±3.12) mmol/L,(110.25±22.51) μmol/L and(111.82±39.56) mg/g in the control group, with statistically significant differences(P< 0.05). Conclusion Sacubitril/valsartancan effectively control blood pressure of patients with hypertension complicated with CKD, improve renal function, and have fewer adverse reactions, which is worthy of clinical application.

关 键 词：沙库巴曲缬沙坦 慢性肾脏病 高血压 肾功能 

分 类 号：R544.1[医药卫生—心血管疾病] R692[医药卫生—内科学]